Roche

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics
Xconomy
Tue, 11/27/18 - 11:41 pm
Roche
Jecure Therapeutics
M&A
NASH
Genentech
AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena
Fierce Pharma
Mon, 11/26/18 - 12:35 pm
AbbVie
Venclexta
Roche
AML
FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia
Yahoo/Guru Focus
Sat, 11/24/18 - 01:27 pm
Roche
Genentech
Venclexta
FDA
AML
acute myeloid leukemia
Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug
Endpoints
Wed, 11/21/18 - 12:20 pm
Roche
hepatitis B
China
Hong Kong
Ascletis
Pegasys
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Fierce Pharma
Tue, 11/20/18 - 12:15 pm
Roche
Merck
Pfizer
Tecentriq
kidney cancer
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
BioSpace
Mon, 11/19/18 - 11:25 am
Tesaro
Roche
Gilead Sciences
M&A
Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug
Fierce Biotech
Mon, 11/19/18 - 09:54 am
Genentech
Roche
MAGE-A4
IMC-C103C
Immunocore
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Tue, 11/13/18 - 09:51 am
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'
Endpoints
Fri, 11/9/18 - 12:15 pm
Genentech
Roche
JHL Biotech
trade secrets
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Mon, 11/5/18 - 11:53 am
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Sat, 11/3/18 - 04:05 pm
Celgene
Revlimid
Roche
Rituxan
follicular lymphoma
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Sat, 11/3/18 - 12:39 pm
Novartis
Sandoz
rituximab
biosimilars
Roche
Roche and AbbVie Push Towards First-Line CLL Treatment
BioSpace
Thu, 11/1/18 - 11:28 am
Roche
Genentech
AbbVie
clinical trials
Venclexta
Gazyva
CLL
chronic lymphocytic leukemia
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Mon, 10/29/18 - 10:27 am
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
Pharmaforum
Fri, 10/26/18 - 09:54 am
NICE
AbbVie
Venclyxto
Roche
Rituxan/MabThera
CLL
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Thu, 10/25/18 - 11:43 am
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
Wed, 10/24/18 - 01:21 pm
FDA
Xofluza
Flu
Shionogi
Roche
Tamiflu
FDA Approves First New Flu Drug in Nearly 20 Years
Wed, 10/24/18 - 12:39 pm
Shionogi
Roche
Xofluza
Tamiflu
influenza
Not So Fast With Immune Therapy For Breast Cancer
Forbes
Mon, 10/22/18 - 11:14 pm
breast cancer
immunotherapy
Roche

Pages